The effects of pharmacological interventions on quality of life and fatigue in sarcoidosis: a systematic review
| العنوان: | The effects of pharmacological interventions on quality of life and fatigue in sarcoidosis: a systematic review |
|---|---|
| المؤلفون: | Vis, Roeland, van de Garde, Ewoudt M W, Grutters, Jan C, Korenromp, Ingrid H E, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology |
| المساهمون: | Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology |
| المصدر: | European Respiratory Review, Vol 29, Iss 155 (2020) European Respiratory Review, 29(155). European Respiratory Society |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Pulmonary and Respiratory Medicine, medicine.medical_specialty, MEDLINE, Psychological intervention, 03 medical and health sciences, 0302 clinical medicine, Quality of life, Refractory, Sarcoidosis, Pulmonary, Internal medicine, medicine, Humans, In patient, 030212 general & internal medicine, Lung, Fatigue, lcsh:RC705-779, business.industry, Recovery of Function, lcsh:Diseases of the respiratory system, medicine.disease, Outcome parameter, Pharmacological interventions, Functional Status, Treatment Outcome, 030228 respiratory system, Quality of Life, Sarcoidosis, business |
| الوصف: | AimsMany sarcoidosis patients experience a reduction in health-related quality of life (HRQoL) and a majority of patients report fatigue. Historically, drug trials in sarcoidosis have focused on changes in chest radiographs, lung function parameters and biomarkers, while HRQoL and fatigue have not been the main outcomes examined. We performed a systematic review of the literature to evaluate the existing evidence on the effects of pharmacological interventions on HRQoL and fatigue outcomes.MethodsThe systematic search was performed in Medline and Embase and yielded 15 records covering seven randomised controlled trials and seven single-arm open label studies, which were included in a qualitative synthesis (the results of one study were included in two publications). 12 studies evaluated immunosuppressive and/or immunomodulatory therapies and two studies evaluated stimulants.ResultsNine out of the 14 studies observed positive treatment effects from the interventions on HRQoL and/or fatigue, exceeding the minimal important difference. The risk of bias was generally high with only three studies rated as having a low risk of bias. The results suggest a potential for improvement in HRQoL and/or fatigue in patients with active disease who are either untreated or treated but not yet fully stabilised or therapy refractory.ConclusionMore randomised, double-blind and placebo-controlled trials are needed to expand the evidence base on these important outcome parameters. |
| وصف الملف: | image/pdf |
| اللغة: | English |
| تدمد: | 0905-9180 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ed09ec88022e6d12ecffc8489cde237 https://hdl.handle.net/1874/395180 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....3ed09ec88022e6d12ecffc8489cde237 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 09059180 |
|---|